UKUK

100% premium: Novartis buys antibiotics specialists Neutec Pharma

21.07.2006

London – Another UK biotech company was taken over when Novartis signed a recommended all-cash offer worth Euro435 million for the antibiotics specialists Neutec pharma. The Swiss pharma giant paid more than twice of the Manchester-based company’s market capitalization before the takeover approach. Buying Neutec gives Novartis access to two advanced stage antibody products for serious hospital-acquired infections: Mycograb, for treating systemic fungal infections and Aurograb, for treating methicillin-resistant Staphylococcus aureus. Daniel Vasella, CEO of Novartis, said the products “promise to dramatically improve treatments in the area and will also enable Novartis to strengthen its biologics pipeline and anti-infective drug portfolio.” Mycograb has been filed in Europe and has been approved for compassionate use, while Aurograb is in phase III. NeuTec has retained 100% ownership of its products. The buyout is a big payday for the founders Ruth Mathews and James Burnie, who still own a 7% stake. During the takeover negotiations the founders secured NeuTecs operations at the current facility in Manchester for at least two years. The sale of the company came just three weeks after AstraZeneca agreed to buy Cambridge Antibody for Euro1.1 billion. Besides the Neutec deal the antibiotics market has seen amany known players disappear. One of the most prominent was the US-based Vicuron, bought by Pfizer for $1.9 billion. New companies have nevertheless emerged as Roche (Basilea), Sanofi-Aventis (Novexel), Sandoz (Nabriva) and Bayer (Aicuris) span out their infectious disease businesses.

BioFunding

12.06.2011

Oslo/Vaulx-en-Velin – An international consortium led by Norwegian company Epitarget AS has been awarded a EUR1.1m grant from the European Union. Together with French partners EDAP TMS S.A. and Inserm, the drug delivery...

BioFunding

12.06.2011

On the eve of 2011’s ASCO meeting – always a good trigger for sentiment – bio­tech investors have already had a good ride – especially those who invested in the United States. Both US biotech indices (NYSE Arca & Nasdaq) have...

BioPeople

12.06.2011

Catherine Moukheibir has been named Senior Advisor Finance to Marseille-based Innate Pharma SA’s executive board. Prior to joining Innate Pharma, Mrs Moukheibir was CFO of Belgian public company Movetis. Before that, she was a...

Tech Review

12.06.2011

The ability to analyze more than one cellular biomarker in the same cell culture sample well is advantageous for a number of reasons. Multiplexing allows researchers to save money and time while conserving precious samples. In...

Politics / Law

11.06.2011

Munich – Patent filings at the European Patent Office (EPO) reached an all-time high in 2010. Some 39% of them originated from the 38 member states of the European Patent Organisation, 26% from the US, 18% from Japan and 5% each...

BioFunding

11.06.2011

Brussels – EU researchers have kicked off a EUR3m project aimed at providing a safety check for new nanomaterials. “InLiveTox” is set to deliver the very first in vitro system that mimicks transport of nanomaterials across cell...

BioFunding

11.06.2011

Brussels – In the latest call launched for health in FP7 (‘Innovative Health Research’), the European Commission appears to be putting its money where its mouth is for biotech SMEs. I (and most others) have always known that...

BioFunding

11.06.2011

Berne – In 2010, researchers in Switzerland submitted substantially more projects to the Swiss National Science Foundation (SNSF) than in previous years. Biologists and medical researchers were among the most active applicants....

Clinical Trial

11.06.2011

French TxCell SA (Valbonne) has received the green light from regulatory authorities to extend a Phase I/II clinical trial of its T-cell-based treatment Ovasave in recurrent Crohn’s Disease. The CATS 1 trial, which was completed...

BioPeople

11.06.2011

Swiss monoclonal antibody specialist NovImmune SA (Plan-Les-Ouates) has announced Klaus Strein will be joining its board of directors. Strein launched Roche’s Therapeutic Protein Initiative, and is currently in charge of all...

Displaying results 141 to 150 out of 1983

< Previous 141-150 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/14/article/100-premium-novartis-buys-antibiotics-specialists-neutec-pharma.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 25.10.2014


Current issue

All issues

Product of the week

Products